1-3 of 3
Manuel Albors
Close
Sort by
Journal Articles

Impact of Treatment on Overall Survival (OS) in Higher-Risk Myelodysplastic Syndromes (MDS): A Report from the Erasme Study

Montserrat Arnan, MD PhD, Rosa Coll, MD, Mar Tormo, MD PhD, José María Bastida, MD, María Calbacho, MD, Teresa Bernal, MD, Fernando Ramos, MD PhD MPH, Nieves Somolinos, MD, Carmen Pedro, MD, Manuel Albors, MD, Inmaculada Marchante, MD, Salut Brunet, MD PhD, Montse Rafel, David Valcárcel, MD PhD
Journal: Blood
Blood (2015) 126 (23): 5240.
https://doi.org/10.1182/blood.V126.23.5240.5240
Published: 2015
Journal Articles

IMPACT of Therapeutic Strategy and Time to Therapy Initiation on Clinical Evolution in Higher-Risk Myelodysplastic Syndromes. a Report from Erasme Study

Julia Montoro, MD, Rosa Coll, MD, David Valcarcel, MD PhD, Mar Tormo, MD, Maria Calbacho, MDPhD, Teresa Bernal, MD, Alfonso Fernandez, Joaquin Sanchez, MD, Manuel Albors, Montserrat Arnan, MD, Edgardo Barranco, Montse Rafel, Regina Garcia, MD
Journal: Blood
Blood (2014) 124 (21): 1908.
https://doi.org/10.1182/blood.V124.21.1908.1908
Published: 2014
Journal Articles

Prognostic Significance of Promoter Methylation of Multiple Genes in Germinal Center Hyperplasia (GCH) and Lymphomas of Germinal Center Origin.

Jose M Paz-Carreira, MD, PhD, Arantxa Garcia-Rivero, PhD, Raquel Losada, PhD, Jose C Mendez, MD, Manuel Albors, MD, Fatima Miras, MD, Augusto Alvarez, MD, Fernando Bal, MD, Jesus Alba, MD, PhD, Guillermo Deben, MD
Journal: Blood
Blood (2009) 114 (22): 3950.
https://doi.org/10.1182/blood.V114.22.3950.3950
Published: 2009